CD274 and neoplasm: At present, patients with stage IV disease can be treated with ICB monotherapy if PD-L1 is expressed in ≥50% of tumor cells, whereas chemotherapy and ICB combinations and combined ICB can be administered regardless of PD-L1 expression [3, 4].